Maravai LifeSciences Holdings, Inc. (MRVI) PEG Ratio
N/A
PE ratio relative to earnings growth — is the valuation justified?
—
PEG Ratio
Negative earnings — PE and PEG ratios are not meaningful
—
Current Price
$4.80
TTM EPS
$-0.54
P/E Ratio
—
Growth Rate
—
N/A
Sector
Healthcare
Biotechnology
Calculated
8/20/2026
4:48:44 AM
PEG Ratio Unavailable
Insufficient price/EPS data
Peer Comparison
Sample Size
2 peers
Industry Median PEG
0.64
25th Percentile
0.40
75th Percentile
0.88
Symbol
Company
PEG
P/E
Growth
vs MRVI
SHC
Sotera Health Company
0.40
27.4
68.8%
—
HALO
Halozyme Therapeutics, Inc.
0.88
19.9
22.7%
—
How to Interpret PEG Ratio
PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.
PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."
PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.
Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.
